Depomed, Inc.

Pharmaceutical company sues Biovail for breach of contract

Published in Medicine and Law Weekly, December 16th, 2005

Depomed, Inc., (DEPO) has filed a complaint in California Superior Court for San Mateo County against Biovail Corp. and its subsidiary, Biovail Laboratories International, relating to Biovail's alleged breaches of the parties' 2002 license agreement, as amended, for Glumetza, a once-daily extended-release formulation of metformin approved for the treatment of type II diabetes.

The complaint asserts breach of contract and related claims, and seeks damages, and a declaration that Depomed is entitled to terminate the contract as a result of Biovail's breaches of the agreement.

Depomed stated it remains interested in discussing with Biovail a resolution...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2005-12-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry